| Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges LC Gomes-da-Silva, NA Fonseca, V Moura, MC Pedroso de Lima, ... Accounts of chemical research 45 (7), 1163-1171, 2012 | 273 | 2012 |
| Antibacterial activity of chitosan nanofiber meshes with liposomes immobilized releasing gentamicin N Monteiro, M Martins, A Martins, NA Fonseca, JN Moreira, RL Reis, ... Acta biomaterialia 18, 196-205, 2015 | 197 | 2015 |
| Current challenges and emerging opportunities of CAR-T cell therapies TR Abreu, NA Fonseca, N Gonçalves, JN Moreira Journal of Controlled Release 319, 246-261, 2020 | 136 | 2020 |
| Instructive nanofibrous scaffold comprising runt-related transcription factor 2 gene delivery for bone tissue engineering N Monteiro, D Ribeiro, A Martins, S Faria, NA Fonseca, JN Moreira, ... Acs Nano 8 (8), 8082-8094, 2014 | 100 | 2014 |
| Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination NA Fonseca, AS Rodrigues, P Rodrigues-Santos, V Alves, AC Gregório, ... Biomaterials 69, 76-88, 2015 | 91 | 2015 |
| Nucleolin-based targeting strategies for cancer therapy: from targeted drug delivery to cytotoxic ligands S Romano, N Fonseca, S Simoes, J Goncalves, JN Moreira Drug Discovery Today 24 (10), 1985-2001, 2019 | 77 | 2019 |
| Immobilization of bioactive factor-loaded liposomes on the surface of electrospun nanofibers targeting tissue engineering N Monteiro, A Martins, R Pires, S Faria, NA Fonseca, JN Moreira, RL Reis, ... Biomaterials Science 2 (9), 1195-1209, 2014 | 71 | 2014 |
| Bridging cancer biology and the patients' needs with nanotechnology-based approaches NA Fonseca, AC Gregorio, A Valerio-Fernandes, S Simoes, JN Moreira Cancer Treatment Reviews 40 (5), 626-635, 2014 | 61 | 2014 |
| Inoculated cell density as a determinant factor of the growth dynamics and metastatic efficiency of a breast cancer murine model AC Gregório, NA Fonseca, V Moura, M Lacerda, P Figueiredo, S Simões, ... PLoS One 11 (11), e0165817, 2016 | 59 | 2016 |
| Cancer stem cells and nucleolin as drivers of carcinogenesis LS Carvalho, N Gonçalves, NA Fonseca, JN Moreira Pharmaceuticals 14 (1), 60, 2021 | 48 | 2021 |
| On the use of dexamethasone‐loaded liposomes to induce the osteogenic differentiation of human mesenchymal stem cells N Monteiro, A Martins, D Ribeiro, S Faria, NA Fonseca, JN Moreira, ... Journal of Tissue Engineering and Regenerative Medicine 9 (9), 1056-1066, 2015 | 48 | 2015 |
| Simultaneous active intracellular delivery of doxorubicin and C6-ceramide shifts the additive/antagonistic drug interaction of non-encapsulated combination NA Fonseca, LC Gomes-da-Silva, V Moura, S Simoes, JN Moreira Journal of Controlled Release 196, 122-131, 2014 | 47 | 2014 |
| Cell surface Nucleolin represents a novel cellular target for neuroblastoma therapy C Brignole, V Bensa, NA Fonseca, G Del Zotto, S Bruno, AF Cruz, ... Journal of Experimental & Clinical Cancer Research 40 (1), 180, 2021 | 39 | 2021 |
| The cancer stem cell phenotype as a determinant factor of the heterotypic nature of breast tumors NA Fonseca, AF Cruz, V Moura, S Simoes, JN Moreira Critical reviews in oncology/hematology 113, 111-121, 2017 | 38 | 2017 |
| New integrative computational approaches unveil the Saccharomyces cerevisiae pheno-metabolomic fermentative profile and allow strain selection for winemaking R Franco-Duarte, L Umek, I Mendes, CC Castro, N Fonseca, R Martins, ... Food Chemistry 211, 509-520, 2016 | 32 | 2016 |
| GMP-grade nanoparticle targeted to nucleolin downregulates tumor molecular signature, blocking growth and invasion, at low systemic exposure NA Fonseca, AC Gregório, VM Mendes, R Lopes, T Abreu, N Gonçalves, ... Nano Today 37, 101095, 2021 | 20 | 2021 |
| Rational formulation and industrial manufacturing of lipid-based complex injectables: Landmarks and trends M Biscaia-Caleiras, NA Fonseca, AS Lourenço, JN Moreira, S Simões Journal of Controlled Release 373, 617-639, 2024 | 12 | 2024 |
| The enhanced efficacy of intracellular delivery of doxorubicin/C6-ceramide combination mediated by the F3 peptide/nucleolin system is supported by the downregulation of the … AF Cruz, MB Caleiras, NA Fonseca, N Goncalves, VM Mendes, ... Cancers 13 (12), 3052, 2021 | 12 | 2021 |
| Modelling the impact of nucleolin expression level on the activity of F3 peptide-targeted pH-sensitive pegylated liposomes containing doxorubicin R Lopes, K Shi, NA Fonseca, A Gama, JS Ramalho, L Almeida, V Moura, ... Drug Delivery and Translational Research, 1-18, 2022 | 10 | 2022 |
| Nucleolin overexpression predicts patient prognosis while providing a framework for targeted therapeutic intervention in lung cancer  Valério-Fernandes, NA Fonseca, N Gonçalves, AF Cruz, MI Pereira, ... Cancers 14 (9), 2217, 2022 | 9 | 2022 |
Nuno M. Neves3B's Research Group/University of MinhoAdresă de e-mail confirmată pe dep.uminho.pt
